Medical Oncology
Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.
Related Videos
Video
Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101
Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.
Video
Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis
Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.
Video
Kidney Cancer Highlights from ESMO 2023
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2023.
Video
ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.
Video
ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD
We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.
Video
Kidney Cancer Highlights from ESMO 2022
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Video
Toni Choueiri, MD Shares the Latest Data From COSMIC-313
Kidney Cancer triplet slows progression in advanced disease when compared to immunotherapy combo (nivolumab + ipilimumab).
Video
COVID-19 and Cancer: Breakthrough Infections
New study: Fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death. Dana-Farber's Toni Choueiri, MD, highlights the research.
Video
Kidney Cancer Research at ESMO
Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.
